Cellectis (CLLS) Competitors $2.95 +0.44 (+17.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.06 +0.11 (+3.73%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLLS vs. TBPH, SAGE, PRME, RZLT, UPXI, SLDB, KURA, ORKA, TERN, and OPTShould you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Prime Medicine (PRME), Rezolute (RZLT), Upexi (UPXI), Solid Biosciences (SLDB), Kura Oncology (KURA), Oruka Therapeutics (ORKA), Terns Pharmaceuticals (TERN), and Opthea (OPT). These companies are all part of the "pharmaceutical products" industry. Cellectis vs. Its Competitors Theravance Biopharma Sage Therapeutics Prime Medicine Rezolute Upexi Solid Biosciences Kura Oncology Oruka Therapeutics Terns Pharmaceuticals Opthea Cellectis (NASDAQ:CLLS) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Is CLLS or TBPH more profitable? Theravance Biopharma has a net margin of -89.38% compared to Cellectis' net margin of -114.82%. Theravance Biopharma's return on equity of -32.37% beat Cellectis' return on equity.Company Net Margins Return on Equity Return on Assets Cellectis-114.82% -62.55% -21.19% Theravance Biopharma -89.38%-32.37%-16.48% Do insiders and institutionals hold more shares of CLLS or TBPH? 63.9% of Cellectis shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 6.9% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, CLLS or TBPH? Cellectis has a beta of 3.03, meaning that its stock price is 203% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Which has better earnings & valuation, CLLS or TBPH? Cellectis has higher earnings, but lower revenue than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectis$49.22M3.33-$36.76M-$0.86-3.43Theravance Biopharma$64.38M8.47-$56.42M-$1.18-9.24 Does the media favor CLLS or TBPH? In the previous week, Cellectis had 2 more articles in the media than Theravance Biopharma. MarketBeat recorded 4 mentions for Cellectis and 2 mentions for Theravance Biopharma. Cellectis' average media sentiment score of 0.42 beat Theravance Biopharma's score of 0.00 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Theravance Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend CLLS or TBPH? Cellectis currently has a consensus target price of $4.00, suggesting a potential upside of 35.59%. Theravance Biopharma has a consensus target price of $16.60, suggesting a potential upside of 52.29%. Given Theravance Biopharma's higher possible upside, analysts clearly believe Theravance Biopharma is more favorable than Cellectis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.67 SummaryTheravance Biopharma beats Cellectis on 9 of the 17 factors compared between the two stocks. Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLLS vs. The Competition Export to ExcelMetricCellectisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.51M$3.00B$5.47B$9.53BDividend YieldN/A2.44%4.74%4.08%P/E Ratio-3.4317.6228.6723.80Price / Sales3.33269.12422.3188.12Price / CashN/A41.9535.4557.96Price / Book1.258.508.275.55Net Income-$36.76M-$55.06M$3.24B$259.03M7 Day Performance17.06%-3.98%-3.63%-4.56%1 Month Performance78.79%9.59%4.40%4.49%1 Year Performance41.83%6.72%25.97%18.05% Cellectis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLLSCellectis2.5557 of 5 stars$2.95+17.5%$4.00+35.6%+36.6%$139.51M$49.22M-3.43290Upcoming EarningsGap UpTBPHTheravance Biopharma1.7973 of 5 stars$11.06+0.3%$16.60+50.1%+8.7%$551.52M$64.38M0.00110Upcoming EarningsSAGESage Therapeutics3.7225 of 5 stars$8.78-0.2%$8.02-8.7%-11.0%$551.06M$41.24M0.00690News CoveragePositive NewsEarnings ReportPRMEPrime Medicine3.7286 of 5 stars$4.09-2.9%$9.25+126.2%-22.2%$550.09M$3.85M-2.00234News CoveragePositive NewsInsider TradeRZLTRezolute2.3449 of 5 stars$6.38+1.3%$11.83+85.5%+33.1%$548.08MN/A0.0040UPXIUpexi3.7559 of 5 stars$5.88-3.8%$16.00+172.1%-32.3%$546M$26M0.00130Positive NewsInsider TradeGap DownSLDBSolid Biosciences2.6433 of 5 stars$7.02+0.3%$15.10+115.1%-20.9%$542.61M$8.09M0.00100Gap DownKURAKura Oncology3.3333 of 5 stars$6.20-0.5%$24.50+295.2%-70.2%$539.36M$53.88M0.00130News CoveragePositive NewsUpcoming EarningsORKAOruka Therapeutics2.2575 of 5 stars$14.01-1.7%$40.38+188.2%N/A$533.53MN/A0.00N/AUpcoming EarningsTERNTerns Pharmaceuticals3.5737 of 5 stars$5.95-1.7%$15.63+162.6%-29.6%$528.39MN/A0.0040Positive NewsUpcoming EarningsOPTOpthea0.3208 of 5 stars$3.41+7.2%$1.33-60.9%+53.2%$524.84M$120K0.008Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies TBPH Alternatives SAGE Alternatives PRME Alternatives RZLT Alternatives UPXI Alternatives SLDB Alternatives KURA Alternatives ORKA Alternatives TERN Alternatives OPT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLLS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
